1887

Abstract

Purpose. Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen causing an increasing number of nosocomial infections. Our aim was to evaluate the risk factors and mechanisms associated with trimethoprim–sulfamethoxazole (SXT) resistance in S. maltophilia infections in Mexico.

Methodology. Clinical isolates and patients' demographic and clinical data were collected from February 2007 to August 2015 in two tertiary-care hospitals in Mexico. Antimicrobial susceptibility and analysis of sul and SmeABC and SmeDEF efflux pump overexpression were performed in all isolates.

Results/Key findings. In the 9-year period, 196 patients infected with S. maltophilia were identified. Most patients were male, and the mean age was 46.2 years. The mean Charlson score was 1.42, and the most frequent comorbidities were arterial hypertension (26.7 %), type 2 diabetes (21.2 %) and cerebral infarction (11.6 %). High drug resistance to meropenem (93.4 %), gentamicin (55.1 %), ceftazidime (52.3 %), cefotaxime (51.5 %), amikacin (42.3 %) and cefepime (32.1 %), and lower resistance to ciprofloxacin (26.0 %), SXT (25.0 %), chloramphenicol (14.3 %) and levofloxacin (2.6 %) were detected. SXT resistance was not associated with the sul genes. SmeABC overexpression was associated with gentamicin (P=0.001) and levofloxacin resistance (P=0.041), whereas SmeDEF overexpression was associated with ceftazidime resistance (P=0.003). Prolonged hospitalization (≥15 days) was an independent risk factor for SXT-resistant S. maltophilia infections (OR=3.05; 95 % CI=1.12–8.86; P=0.029).

Conclusion. Given the high SXT resistance rate, SXT is not an effective first-line therapy for our patients; instead, levofloxacin could be used as an appropriate therapeutic option against S. maltophilia infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000550
2017-08-04
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/8/1102.html?itemId=/content/journal/jmm/10.1099/jmm.0.000550&mimeType=html&fmt=ahah

References

  1. Senol E, Desjardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002;34:1653–1656 [CrossRef][PubMed]
    [Google Scholar]
  2. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM et al. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009;4:1103–1109 [CrossRef][PubMed]
    [Google Scholar]
  3. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57–80[PubMed]
    [Google Scholar]
  4. Nseir S, di Pompeo C, Brisson H, Dewavrin F, Tissier S et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006;10:R143 [CrossRef][PubMed]
    [Google Scholar]
  5. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007;26:229–237 [CrossRef][PubMed]
    [Google Scholar]
  6. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010;54:2735–2737 [CrossRef][PubMed]
    [Google Scholar]
  7. Hu LF, Chen GS, Kong QX, Gao LP, Chen X et al. Increase in the prevalence of resistance determinants to Trimethoprim/Sulfamethoxazole in clinical Stenotrophomonas maltophilia Isolates in China. PLoS One 2016;11:e0157693 [CrossRef][PubMed]
    [Google Scholar]
  8. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015;6:893 [CrossRef][PubMed]
    [Google Scholar]
  9. Cho HH, Sung JY, Kwon KC, Koo SH. Expression of Sme efflux pumps and multilocus sequence typing in clinical isolates of Stenotrophomonas maltophilia. Ann Lab Med 2012;32:38–43 [CrossRef][PubMed]
    [Google Scholar]
  10. Chang LL, Chen HF, Chang CY, Lee TM, Wu WJ. Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2004;53:518–521 [CrossRef][PubMed]
    [Google Scholar]
  11. Alonso A, Martínez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000;44:3079–3086 [CrossRef][PubMed]
    [Google Scholar]
  12. Sánchez MB, Martínez JL. The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2015;59:4347–4348 [CrossRef][PubMed]
    [Google Scholar]
  13. Chung HS, Kim K, Hong SS, Hong SG, Lee K et al. The sul1 gene in Stenotrophomonas maltophilia with high-level resistance to trimethoprim/sulfamethoxazole. Ann Lab Med 2015;35:246–249 [CrossRef][PubMed]
    [Google Scholar]
  14. Jorgensen JH, Carroll KC, Pfaller MA. Manual of Clinical Microbiology Washington, DC: ASM Press; 2015;[CrossRef]
    [Google Scholar]
  15. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383 [CrossRef][PubMed]
    [Google Scholar]
  16. Rios-Licea MM, Bosques FJ, Arroliga AC, Galindo-Galindo JO, Garza-Gonzalez E. Quadruplex real-time quantitative PCR assay for the detection of pathogens related to late-onset ventilator-associated pneumonia: a preliminary report. J Microbiol Methods 2010;81:232–234 [CrossRef][PubMed]
    [Google Scholar]
  17. CLSI Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016
    [Google Scholar]
  18. Wang CH, Lin JC, Lin HA, Chang FY, Wang NC et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: a 10-year retrospective study. J Microbiol Immunol Infect 2016;49:378–386 [CrossRef][PubMed]
    [Google Scholar]
  19. Hotta G, Matsumura Y, Kato K, Nakano S, Yunoki T et al. Risk factors and outcomes of Stenotrophomonas maltophilia bacteraemia: a comparison with bacteraemia caused by Pseudomonas aeruginosa and Acinetobacter species. PLoS One 2014;9:e112208 [CrossRef][PubMed]
    [Google Scholar]
  20. Flores-Treviño S, Gutiérrez-Ferman JL, Morfín-Otero R, Rodríguez-Noriega E, Estrada-Rivadeneyra D et al. Stenotrophomonas maltophilia in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. J Med Microbiol 2014;63:1524–1530 [CrossRef][PubMed]
    [Google Scholar]
  21. Cho SY, Kang CI, Kim J, Ha YE, Chung DR et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?. Antimicrob Agents Chemother 2014;58:581–583 [CrossRef][PubMed]
    [Google Scholar]
  22. Chong SY, Lee K, Chung HS, Hong SG, Suh Y et al. Levofloxacin Efflux and smeD in clinical isolates of Stenotrophomonas maltophilia. Microb Drug Resist 2017;23:163–168 [CrossRef][PubMed]
    [Google Scholar]
  23. Liaw SJ, Lee YL, Hsueh PR. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation. Int J Antimicrob Agents 2010;35:126–130 [CrossRef][PubMed]
    [Google Scholar]
  24. Perreten V, Boerlin P. A new sulfonamide resistance gene (sul3) in Escherichia coli is widespread in the pig population of Switzerland. Antimicrob Agents Chemother 2003;47:1169–1172 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000550
Loading
/content/journal/jmm/10.1099/jmm.0.000550
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error